Bristol-Myers Squibb completes Amira acquisition

NEW YORK — Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.

Bristol said it has completed the acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals, based in San Diego, for $325 million. Amira's portfolio focuses on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

The transaction was originally announced on July 21.